Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Diabetes Mellitus · Hemophilia A

Takeda

Takeda clinical programs — 393 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Cambridge, USA HQ
1993 Founded
1,617 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Cambridge, USA
Founded
1993
Employees
1,617
Programs
1179
Drugs
359
Patents
1436
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Takeda projects

393 ClinicalTrials.gov programs sponsored by Takeda.

Takeda has 393 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

393 programs

Clinical programs

Page 5 of 9

  1. Placebo

    Takeda

    Chronic Idiopathic Constipation

    phase 3 small molecule completed

    1 trial

  2. Placebo

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  3. Placebo

    Takeda

    Diabetes

    phase 3 small molecule terminated

    1 trial

  4. Placebo

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    2 trials

  5. Placebo

    Takeda

    Generalized Anxiety Disorder

    phase 3 small molecule completed

    1 trial

  6. Placebo

    Takeda

    Healthy Volunteers

    phase 3 small molecule completed

    2 trials

  7. Placebo

    Takeda

    Hypertension

    phase 3 small molecule terminated

    1 trial

  8. Placebo

    Takeda

    Hypoparathyroidism

    phase 3 small molecule completed

    1 trial

  9. Placebo

    Takeda

    Lennox Gastaut Syndrome (LGS)

    phase 3 small molecule completed

    1 trial

  10. Placebo

    Takeda

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

  11. Placebo

    Takeda

    Male Subjects With Chronic Constipation

    phase 3 small molecule completed

    1 trial

  12. Placebo

    Takeda

    Multiple Myeloma

    phase 3 small molecule completed

    1 trial

  13. Placebo

    Takeda

    Non-erosive Gastroesophageal Reflux Disease

    phase 3 small molecule completed

    1 trial

  14. Placebo

    Takeda

    Short Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  15. Ponatinib

    Takeda

    Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 3 small molecule active

    1 trial

  16. Ponatinib 30 mg QD

    Takeda

    Chronic Phase Chronic Myeloid Leukemia

    phase 3 small molecule terminated

    1 trial

  17. Ponatinib-3001

    Takeda

    Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

    phase 3 small molecule active

    1 trial

  18. Protein C Concentrate (Human) Vapor Heated

    Takeda

    Protein C Deficiency

    phase 3 small molecule completed

    1 trial

  19. Prucalopride

    Takeda

    Constipation

    phase 3 small molecule terminated

    1 trial

  20. Ramelteon

    Takeda

    Transient Insomnia

    phase 3 small molecule completed

    1 trial

  21. Ramelteon

    Takeda

    Sleep Initiation and Maintenance Disorders

    phase 3 small molecule completed

    2 trials

  22. Ramelteon

    Takeda

    Balance

    phase 3 small molecule completed

    1 trial

  23. Ramelteon SL

    Takeda

    Acute Depressive Episode

    phase 3 small molecule terminated

    1 trial

  24. Ramelteon SL

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  25. Ramelteon SL (Dose 1)

    Takeda

    Bipolar Disorder

    phase 3 small molecule terminated

    1 trial

  26. Ramelteon and Placebo (9 possible combinations total)

    Takeda

    Chronic Insomnia

    phase 3 small molecule completed

    1 trial

  27. Recombinant Factor VIIa BI (rFVIIa BI)

    Takeda

    Hemophilia A

    phase 3 mab completed

    1 trial

  28. Recombinant factor IX

    Takeda

    Hemophilia B

    phase 3 mab completed

    1 trial

  29. Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 3 mab completed

    1 trial

  30. Recombinant von Willebrand factor (rVWF)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    2 trials

  31. Relugolix

    Takeda

    Uterine Fibroids

    phase 3 small molecule completed

    2 trials

  32. Resatorvid

    Takeda

    Sepsis

    phase 3 small molecule completed

    2 trials

  33. Rituximab 375 mg/m^2

    Takeda

    Mantle Cell Lymphoma

    phase 3 small molecule completed

    1 trial

  34. SALINE, Fazirsiran

    Takeda

    Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

    phase 3 small molecule active

    1 trial

  35. SHP465

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    4 trials

  36. SHP465 12.5mg capsules (one capsule daily)

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  37. SHP615

    Takeda

    Nervous System Diseases

    phase 3 small molecule completed

    2 trials

  38. SHP640

    Takeda

    Adenoviral Conjunctivitis

    phase 3 small molecule terminated

    2 trials

  39. SHP640

    Takeda

    Bacterial Conjunctivitis

    phase 3 small molecule completed

    1 trial

  40. SPD422 (anagrelide hydrochloride)

    Takeda

    Essential Thrombocythemia (ET)

    phase 3 small molecule completed

    1 trial

  41. SPD465

    Takeda

    Attention-Deficit/Hyperactivity Disorder

    phase 3 small molecule completed

    2 trials

  42. SPD465-303

    Takeda

    Attention Deficit Disorder With Hyperactivity

    phase 3 small molecule completed

    4 trials

  43. SPD476

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  44. SPD476 (1.2g)

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  45. SPD476 (mesalazine)

    Takeda

    Colitis, Ulcerative

    phase 3 small molecule completed

    1 trial

  46. SPD476-302

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  47. SPD476-314

    Takeda

    Diverticulitis

    phase 3 small molecule completed

    1 trial

  48. SPD489

    Takeda

    Schizophrenia

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

How many clinical projects does Takeda have?

393 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.